View : 102 Download: 0
Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone
- Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone
- Lee H.S.; Kim K.; Lee J.-J.; Yoon S.-S.; Bang S.-M.; Kim J.S.; Eom H.-S.; Yoon D.H.; Lee Y.; Shin H.-J.; Park Y.; Jo J.-C.; Lee W.S.; Do Y.R.; Mun Y.-C.; Lee M.H.; Kim H.J.; Kim S.-H.; Kim M.K.; Lim S.-N.; Park S.K.; Yi J.H.; Lee J.H.; Min C.-K.; The Korean Multiple Myeloma Working Party (KMMWP)
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- International Journal of Hematology
- International Journal of Hematology vol. 113, no. 1, pp. 81 - 91
- Elderly multiple myeloma; Frailty; Lenalidomide and dexamethasone; Relapsed and refractory; Survival
- Springer Japan
- SCIE; SCOPUS
- Document Type
Show the fulltext
- We compared efficacy and safety, according to frailty, of elderly patients with relapsed and refractory multiple myeloma (RRMM) treated with lenalidomide and dexamethasone (Rd), for whom bortezomib treatment had failed. Patients, 164 (52.9%) and 146 (47.1%), were classified as non-frail and frail using a simplified frailty scale. The overall response rates (ORR) and survival outcomes were lower in frail than in non-frail patients (ORR: 56.2% vs. 67.7%, P = 0.069; median progression free survival: 13.17 vs. 17.80 months, P = 0.033; median overall survival: 23.00 vs. 36.27 months, P = 0.002, respectively). The number of treatment emergent adverse events in grade 3 or worse was higher in frail than in non-frail patients (41.8% vs. 24.4%, P = 0.002, respectively). In frail patients, independent poor prognostic factors for survival were two or more Charlson comorbidity index (CCI) score, prior to exposure to both bortezomib and thalidomide, and achieved less than partial response In conclusion, frailty could predict clinical outcomes of Rd treatment in elderly patients with RRMM who had failed prior bortezomib. In frail patients, lower CCI in addition to less previous treatment exposure and deep response were associated with better survival. © 2020, Japanese Society of Hematology.
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.